Drug-drug interaction of direct-acting antivirals in treatment of chronic hepatitis C

With the successful application of direct-acting antivirals (DAAs) in the treatment of hepatitis C, clinical management of drug-drug interaction (DDI) has become a hot topic in this field. Most DAAs develop DDI with other drugs administered at the same time via cytochrome P450 or transporters in the liver and/or the intestine. At present, European Association for the Study of the Liver has published the recommendations on DDI of DAAs in the treatment of chronic hepatitis C, which covers HIV antiretrovirals, lipid-lowering drugs, cardiovascular drugs, immunosuppressants, and addictive drugs for the central nervous system. When developing the regimens for DAA treatment, clinicians should closely assess and monitor the risk of DDI, in order to reduce or avoid treatment failure or adverse reactions during antiviral therapy